Search This Blog

Monday, September 20, 2021

Edesa: Positive Phase 2 Data on Monoclonal Antibody in Hospitalized COVID-19 Patients

 

  • Study unblinded due to strong efficacy signalfor 28-day mortality endpoint

  • Critically ill patients demonstrated a 68.5% reduction in the risk of dying when treated with EB05 over Standard of Care

  • Data monitoring board recommends continuation to confirmatory Phase 3 study

Posted by at

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.

Subscribe to: Post Comments (Atom)